Friday, January 21, 2022
News for Retirees


Biogen Inventory At 2-Yr Low As Medicare Limits Alzheimer’s Protection

Share this…FacebookPinterestTwitterLinkedin Biogen  (BIIB) – Get Biogen Inc. Report shares slumped to a two-year low Wednesday after the U.S. authorities’s Medicare…

By Staff , in Medicare , at January 12, 2022



Biogen  (BIIB) – Get Biogen Inc. Report shares slumped to a two-year low Wednesday after the U.S. authorities’s Medicare program stated it’ll restrict entry to the drugmaker’s newly-approved Alzheimer’s remedy.

The U.S. Facilities for Medicare and Medicaid Companies stated it’ll solely cowl remedy with Aduhelm, Biogen’s Alzheimer’s remedy, if sufferers are enrolled in a scientific trial. The choice, which could possibly be modified after the CMS addresses public feedback in April, would restrict use of the drug that was controversially accepted by the Meals & Drug Administration in June of final yr.





Source link

Skip to content